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Summary. The effects of the non-NMDA glutamate re- 
ceptor antagonist GYKI 52466 (2.4 and 4.8 mg/kg, i.p.) 
on spontaneous locomotor activity and haloperidol-in- 
duced catalepsy (0.5 mg/kg, i.p.) were assessed in naive 
rats and in rats pretreated with the NMDA antagonist 
dizocilpine (0.08 mg/kg, i.p.). GYKI 52466 given alone 
did not alter locomotor activity and haloperidol-induced 
catalepsy, but significantly antagonized the dizocilpine- 
induced locomotor stimulation and counteracted the an- 
ti-cataleptic effects of dizocilpine on haloperidol-induced 
catalepsy. Thus blockade of non-NMDA glutamate re- 
ceptors antagonized the behavioural stimulant effects of 
a NMDA receptor blockade. 
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Introduction 
The synaptic responses elicited by excitatory amino acids 
(EAA) are mediated by different receptor subtypes distin- 
guished according to their preferential agonists as N- 
methyl-D-aspartate (NMDA)-, kainate (KA)-, a-ami- 
no-3-hydroxy-5-methyl-4-isoxazole pr pionate (AMPA)- 
preferring receptors and the metabotropic 1-amino- 
cyclopentane-transdicarboxylate (ACPD) receptor 
(Monaghan et al. 1989). The behavioural pharmacology 
of AMPA and KA subtypes of glutamate receptors, term- 
ed here collectively as non-NMDA receptors, is rarely in- 
vestigated at present. Furthermore little is known about 
the interactions of non-NMDA receptors with NMDA re- 
ceptors or other transmitter systems, e.g. the dopaminer- 
gic system, in behavioural models. The quinoxalinedione 
NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quio- 
noxaline) (Honor~ et al. 1988) and the 2,3-benzodi- 
azepine GYKI 52466 (Tarnawa et al. 1989) are selective 
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antagonists of non-NMDA receptors (Honor6 1991; Tar- 
nawa et al. 1990; Quardouz and Durand 1991). Systemic 
administration of NBQX to drug-naive rats had no or 
even a weak suppressive effect on spontaneous motor be- 
haviour (Klockgether et al. 1991). In animal models or 
Parkinson's disease (PD), NBQX potentiated the an- 
tiparkinson activity of L-DOPA but had no effect or 
even increased hypoactivity when given alone 
(Klockgether et al. 1991; LOschmann et al. 1991). By con- 
trast, systemic administration of NMDA antagonists pro- 
duced a marked behavioural stimulation in drug-naive 
rats (Bubser et al. 1992; Hoffman 1992; Tiedtke et al. 
1990) and reversed parkinsonian symptoms in rodent 
models of PD (Carlsson and Carlsson 1989; Schmidt and 
Bubser 1989; Hauber and Schmidt 1990). The effects of 
NMDA and non-NMDA antagonists are mediated by 
complex actions within the basal ganglia as shown by 
studies using local drug administration (see Schmidt et al. 
1992 for review). On the basis of these findings a block- 
ade of NMDA receptors (Carlsson and Carlsson 1989; 
Schmidt and Bubser 1989) or AMPA receptors 
(Klockgether et al. 1991; LOschmann et al. 1991) was sug- 
gested to provide a new strategy for the treatment of PD. 
In the present study we investigated the effects of a 
blockade of non-NMDA receptors on spontaneous 
locomotor activity and on haloperidol-induced catalepsy 
in rats. Neuroleptic-induced catalepsy may be considered 
as a model of PD because of similarities with the parkin- 
sonian symptoms akinesia and rigidity (Sanberg et al. 
1988). We further examined the effects of a simultaneous 
blockade of NMDA and non-NMDA receptors in these 
behavioural tests. The non-NMDA antagonist GYKI 
52466 and dizocilpine, a potent noncompetitive NMDA 
antagonist, were used to investigate the contribution of 
these glutamate receptor subtypes to the expression of 
motor behaviour. 
Materials and methods 
Animals. Male Sprague-Dawley rats (Interfauna, Tuttlingen, Germany) 
were used weighing 235 -250 g at the start of the experiment. They were 
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housed in groups of four or five per cage with free access to water. Food 
was restricted to 12 g standard laboratory maintenance diet (Altromin, 
Lage, Germany) per animal and day. Rats were housed in a colony room 
maintained at 22_+ 3 °C on a 12:12 light-dark cycle (lights on 06.00 h). 
Behavioural procedure. Spontaneous locomotor activity was assessed 
in an open field (69x69 cm) divided by lines in 9 squares of equal size. 
The open field box was opaque and illuminated by 4 red light bulbs 
(20 W); back ground noise was masked by a fan. An animal was placed 
individually for 10 min into the open field. Locomotor activity was 
monitored by video recording and evaluated by counting the number of 
line crossings during the observation period. 
Catalepsy was measured 30 and 60 min after injection of haloperi- 
dol in three different ests performed in the following order (Scheel- 
Kriiger 1983): 
I. Bar: both forelegs were placed on a horizontal bar (9 cm above the 
surface); II. Podium: one foreleg was placed on a podium (3 cm high); 
III. Grid: an animal was clinged to a vertical wire grid. 
The latency from paw placement until the first movement of one of 
the respective paws (termed here as descent latency) was measured (cut- 
off: 180 s). 
Drugs. Dizocilpine ([+]-5-methyl-10,11-dihydro-5H-dibenzo(a,d)cyclo- 
hepten-5,10-imine) (Biotrend, K01n, Germany) and haloperidol 
(Janssen, Neuss, Germany) were dissolved in physiological saline, re- 
spectively. GYKI 52466 (1-(4-aminophenyl)-4-methyl-7,8-methylendi- 
oxy-5H-2,3-benzodiazepine HC1) obtained from Dr. I. Tarnawa (Inst. 
Drug Research, Hungary) was dissolved in destilled water. Dizocilpine 
(0.08mg/kg, i.p.), GYKI 52466 (2.4 and 4.8mg/kg,  i.p.) and 
haloperidol (0.5 mg/kg, i.p.) were administered alone or in combination 
in a maximum volume of 1 ml 30 rain before the individual onset of the 
behavioral test. Controls in the open field and catalepsy experiment re- 
ceived intraperitoneal injections of saline (1 ml/kg). 
Statistical analysis. Data are presented as means with standard errors of 
the means (_+SEM). The open field data were submitted to an analysis 
of variance (ANOVA) with treatment as factor followed by a Tukey-test 
for comparing means of treatment groups. The catalepsy data were sub- 
mitted to a Mann-Whitney U-test (two-tailed). Differences were consid- 
ered to be significant if the P-value is less then 0.05. 
Results 
Open field 
A one-way ANOVA with treatment as factor followed by 
a Tukey protected t-test revealed that dizocilpine 
(0.08 mg/kg, i.p.) given alone induced a significant in- 
crease of spontaneous locomotor activity (ANOVA: 
P < 0.0005; dizocilpine versus aline: t = - 4.01; P < 0.01). 
Administration of GYKI (2.4 and 4.8 mg/kg, i.p.) did not 
significantly alter spontaneous locomotor activity 
(Fig. 1). 
Administration of GYKI 52466 (2.4 and 4.8 mg/kg, 
i.p.) to animals pretreated with dizocilpine (0.08 mg/kg, 
i.p.) significantly antagonized dizocilpine-induced 
locomotor hyperactivity as shown in Fig. 1 (ANOVA 
P < 0.0001; dizocilpine versus dizocilpine +GYKI 52466 
2.4 mg/kg: t = 5.3, P< 0.01; dizocilpine versus 
dizocilpine plus GYKI 4.8 mg/kg: t = 3.8, P< 0.01). Line 
crossings of all treatment groups are significantly differ- 
ent from the saline group (saline versus dizocilpine: 
t =-8.1;  P<0.01; saline versus dizocilpine plus GYKI 
52466 2.4mg/kg: t=-2 .7 ;  P<0.05; saline versus 
dizocilpine plus GYKI 52466 4.8mg/kg: t=-4 .3 ;  
P<0.01). 
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Fig. 1. Mean number of line crossings (_+SEM) in an open field. Treat- 
merit groups received intraperitoneal injections of saline (1 ml/kg; 
n = 6), dizocilpine (0.08 mg/kg, n = 6) or GYKI 52466 (2.4 mg/kg, 
n = 6 and 4.8 mg/kg, n = 6) (top) or intraperitoneal coinjections of 
dizocilpine (0.8 mg/kg) plus saline (1 ml/kg, n = 6) or dizocilpine 
(0.08 mg/kg) plus GYKI 52466 (2.4mg/kg, n = 6 and 4.8 mg/kg, 
n = 6). Rats with saline injections (1 ml/kg, n = 6) served as controls 
(bottom). *P< 0.01 (ANOVA followed by Tukey's test) 
Catalepsy 
Dizocilpine (0.08 mg/kg, i.p.) given alone exerted a sig- 
nificant anti-cataleptic effect (haloperidol versus 
haloperidol plus dizocilpine: P< 0.007 for each test and 
measurement). 
As shown in Fig. 2 the anti-cataleptic activity of 
dizocilpine was completely reversed by coadministration 
of GYKI 52466 (2.4 mg/kg) (haloperidol plus dizocilpine 
versus haloperidol plus dizocilpine plus GYKI: P<0.01 
for each test and measurement). Results obtained in ani- 
mals treated with haloperidol plus dizocilpine plus GYKI 
were not statistically different from animals treated only 
with haloperidol (P>0.05 for each test and measure- 
ment). The higher dose of GYKI (4.8 mg/kg, i.p.) in com- 
bination with haloperidol and dizocilpine exerted a 
strong muscle relaxant effect. In more then 50°7o of the 
animals it was impossible to perform the grid and bar test 
because animals slipped away due to muscle relaxation. 
In the remaining animals there was a clear tendency for 
a reversal of the anti-cataleptic a tivity of dizocilpine (da- 
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Fig. 2. Mean descent latencies (_+ SEM) in the catalepsy test. Treatment 
groups received intraperitoneal injections of haloperidol (0.5 mg/kg) 
plus saline (1 ml/kg, n = 6), haloperidol (0.5 mg/kg) plus dizocilpine 
(0.08 mg/kg) plus saline (1 ml/kg, n = 6) or haloperidol (0.5 mg/kg) 
plus dizocilpine (0.08 mg/kg) plus GYKI 52466 (2.4mg/kg, n = 5) 
*P<0.01 haloperidol plus dizocipline versus haloperidol plus 
dizocilpine plus GYKI (Mann-Whitney U-test, two-tailed) 
ta not shown). GYKI 52466 given alone in a dose shown 
to potently reverse dizocilpine-induced anticataleptic ef- 
fect did not alter the degree of haloperidol-induced cata- 
lepsy: Mean descent latencies of animals (n = 6) with in- 
jections of GYKI 52466 (2.4 mg/kg, i.p.) plus haloperidol 
(0.5 mg/kg, i.p.) and of animals (n = 5) with injections of 
saline (1 mg/kg, i.p.) plus haloperidol (0.5 mg/kg, i.p.) 
were not different 30 and 60 min after drug administra- 
tion (P>0.05 for each test and measurement, Mann- 
Whitney U-test (data not shown). 
Discussion 
Systemic administration of the non-NMDA antagonist 
GYKI 52466 in doses shown to be anticonvulsant and 
without adverse effects in rodent models of epilepsy 
(Smith et al. 1991) had not effect on spontaneous 
locomotor activity. Furthermore GYKI 52466 given alone 
did not alter the degree of haloperidol-induced catalepsy. 
However, coadministration f GYKI 52466 significantly 
antagonized dizocilpine-induced locomotor hyperactivi- 
ty. In addition, coadministration f GYKI 52466 signifi- 
cantly reversed the anti-cataleptic effect of dizocilpine. 
Thus a blockade of non-NMDA receptors potently re- 
versed the stimulating motor effects induced by a non- 
competitive blockade of NMDA receptors, but did not 
significantly change motor activity when given alone. 
The finding that administration f a non-NMDA an- 
tagonist did not change spontaneous motor activity con- 
firms previous tudies howing that NBQX had no effect 
on or reduced the locomotor activity in drug-naive rats 
(Klockgether t al. 1991) and did not affect motor behav- 
iour in normal monkeys (Greenamyre 1992). In rats with 
unilateral nigral 6-hydroxydopamine lesions or MPTP- 
treated monkeys, systemic administration of NBQX 
reduced rotational behaviour and locomotor activity 
(LOschmann et al. 1991). In addition, NBQX did not im- 
prove akinesia, but suppressed muscular rigidity in 
monoamine-depleted rats(Klockgether et al. 1991) and 
did not antagonize raclopride-induced catalepsy (Papa et 
al. 1993). These findings are congruent with the present 
data showing that GYKI given alone did not antagonize 
haloperidol-induced catalepsy. 
The effects of NBQX in monoamine-depleted rats, in 
rats with nigral 6-hydroxydopamine lesions and in 
MPTP-treated monkeys and the present findings on 
GYKI 52466 in the haloperidol-induced catalepsy argue 
against the view that non-NMDA antagonists given alone 
are useful in the treatment of PD. 
Why systemically administered non-NMDA antago- 
nists did - in contrast to local infusion into basal ganglia 
nuclei- not alter motor activity remains unclear and can- 
not be determined by the present study using systemic ad- 
ministrations. Local administration of non-NMDA an- 
tagonists into basal ganglia output nuclei produced 
marked anti-akinetic effects in animals with parkinso- 
nian symptoms (Brotchie et al. 1991, 1992; Graham et al. 
1990; Klockgether et al. 1991). It was suggested that these 
effects are brought about by a blockade of non-NMDA 
receptors in basal ganglia output nuclei which are overac- 
tive in this condition. On the other hand, the density of 
glutamate receptor subtypes is relatively low in non- 
striatal basal ganglia nuclei. For this reason the efficacy 
of modifying the activity of non-striatal basal ganglia nu- 
clei by systemic administration f EAA antagonists ap- 
pears to be limited (Albin et al. 1992). Studies on the role 
of non-NMDA receptors in basal ganglia nuclei with high 
AMPA/KA receptors densities, i.e. the caudate-putamen 
and the nucleus accumbens showed that local infusion of 
kainate or quisqualate into these structures induced a 
behavioural stimulation (Imperato et al. 1990). In addi- 
tion, local infusion of NBQX into the dorsal striatum did 
not antagonize akinesia in reserpinized rats (Klockgether 
et al. 1991). Therefore non-NMDA receptors in the 
striatum and the nucleus accumbens seem to mediate op- 
posite behavioural effects as non-NMDA receptors in 
basal ganglia output nuclei which is difficult to explain 
with regard to the proposed basal ganglia pathways. Thus 
the contribution of non-NMDA receptors in relevant bas- 
al ganglia nuclei to the behavioural effects of systemically 
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administered non-NMDA antagonists remain obscure at 
present. The present study further evealed that the non- 
NMDA antagonist GYKI 52466 significantly antagonized 
the locomotor stimulation induced by the noncompeti- 
tive NMDA antagonist dizocilpine and abolished the an- 
ticataleptic activity of dizocilpine. The findings on 
dizocilpine-induced locomotor stimulation and anti- 
cataleptic activity replicate similar observations in a num- 
ber of previous reports (e.g. Hauber and Schmidt 1990; 
Hoffman 1992; Schmidt and Bubser 1989; Tiedtke et al. 
1990). The dizocilpine-induced anti-cataleptic activity 
was potently antagonized by the lower dose of GYKI 
52466, while the higher dose of GYKI exerted in this test 
a strong muscle relaxant activity. Although GYKI 52466 
was found to have central muscle relaxant properties (Tar- 
nawa et al. 1989, 1990), no muscle relaxation was ob- 
served when GYKI 52466 had been given alone in the 
doses used here. Thus muscle relaxation seen in the cata- 
lepsy test seems to be due to the combined administration 
of the high dose of GYKI 52466 together with dizocilpine 
and haloperidol. 
Again the mechanisms and sites of action in the basal 
ganglia through which a non-NMDA receptor antagonist 
can inhibit the motor stimulating effects of a NMDA re- 
ceptor blockade are unknown. The striatum is the main 
input structure of the basal ganglia and receives 
glutamatergic inputs from the neocortex. These cortical 
inputs are transmitted via a direct and an indirect striato- 
thalamic route back to the cortex. The direct pathway en- 
compasses neurons from the striatum to the output nuclei 
of the basal ganglia, namely the substantia nigra and the 
entopeduncular nucleus (the rat homologue of the medial 
pallidal segment). The indirect pathway encompasses 
neurons from the striatum to the globus pallidus (the rat 
homologue of the lateral pallidal segment) and via the 
subthalamic nucleus to the basal ganglia output nuclei 
(see Albin et al. 1989 for review). It was recently proposed 
that the direct and indirect pathway are distinct with re- 
gard to the tonicity of their respective glutamatergic in-
puts (Svensson et al. 1992). According to this hypothesis 
the direct pathway which is behaviourally activating re- 
ceives a low glutamatergic input from cortical-striatal 
neurons. By contrast he indirect loop is behaviourally 
suppressive. Glutamatergic cortical neurons impinging on 
striatal neurons of the indirect pathway were suggested to
have a higher activity as compared to cortico-striatal neu- 
rons impinging on the direct pathway (Svensson et al. 
1992). Thus dizocilpine preferentially blocks striatal neu- 
rons which are part of the indirect pathway because the 
higher glutamatergic tonicity enhances the binding prob- 
ability of the open channel blocker dizocilpine. The 
dizo'cilpine binding site is within the NMDA receptor as- 
sociated ion channel and therefore binding of dizocilpine 
depends on channel activation by NMDA receptor stimu- 
lation (see Chen et al. 1992 for references). The 
dizocilpine-induced selective blockade of the behavioural 
suppressive indirect pathway leads then to motor stimula- 
tion (Svensson et al. 1992). Thus a decreased gluta- 
matergic tonicity in the indirect pathway would reduce 
use-dependent binding and behavioural effects of the 
noncompetitive NMDA antagonist dizocilpine. Indeed 
GYKI 52466 was found to reduce xtracellular glutamate 
in the striatum and cortex induced by ischemia in rats. 
This effect is probably due to an inhibition of glutamate 
release via presynaptic kainate receptors (Arvin et al. 
1992). A decreased glutamate release could explain why 
GYKI 52466 reversed izocilpine-induced effects. Howev- 
er it is not known whether GYKI 52466 also reduces glu- 
tamate release in non-ischemic conditions. Furthermore a 
GYKI 52466-induced reduction of glutamate release 
should counteract haloperidol-induced catalepsy in a 
similar way as shown for frontal decortication (Yoshida 
et al. 1991). This was, however, not observed when GYKI 
52466 was given alone, thus making this mechanism un- 
likely. 
An alternative explanation is that GYKI 52466 blocks 
postsynaptic non-NMDA receptors on striatal neurons 
which are part of the indirect loop. A blockade of non- 
NMDA receptors reduces depolarisation which is in turn 
a prerequisite for the voltage-sensitive activation of 
NMDA receptor associated channels and binding of 
dizocilpine (see Headley and Grillner 1991 for review). 
Furthermore, interactions of NMDA and non-NMDA re- 
ceptors in the indirect pathway downstream of the 
striatum may contribute the GYKI 52466-induced rever- 
sal of the dizocilpine ffects. However, the contribution 
of non-striatal EAA receptor subtypes appears to be lim- 
ited due to the low receptor density in non-striatal basal 
ganglia nuclei (see above). 
In summary, systemic administration of a non- 
NMDA antagonist reversed the stimulating motor effects 
induced by a noncompetitive NMDA antagonist. This in- 
teraction is likely to take place within the basal ganglia by 
mechanisms which remain to be detected by studies with 
local drug administration. The present study does not 
support the view of a therapeutic potential for non- 
NMDA antagonists in the treatment of PD when given 
alone. 
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